AOLS (Aeolus Pharmaceuticals) Market Cap: $0.00 Mil (As of Jul. 01, 2026)


What is Aeolus Pharmaceuticals Market Cap?

Aeolus Pharmaceuticals AOLS Market Cap is $0.00 Mil as of Jul. 01, 2026.

Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Aeolus Pharmaceuticals's share price for the quarter that ended in Jun. 2017 was $0.09082. Aeolus Pharmaceuticals's Shares Outstanding (EOP) for the quarter that ended in Jun. 2017 was 152.09 Mil. Therefore, Aeolus Pharmaceuticals's market cap for the quarter that ended in Jun. 2017 was $13.81 Mil.

Aeolus Pharmaceuticals's quarterly market cap declined from Dec. 2016 ($28.90 Mil) to Mar. 2017 ($14.45 Mil) and declined from Mar. 2017 ($14.45 Mil) to Jun. 2017 ($13.81 Mil).

Aeolus Pharmaceuticals's annual market cap declined from Sep. 2014 ($33.96 Mil) to Sep. 2015 ($32.70 Mil) and declined from Sep. 2015 ($32.70 Mil) to Sep. 2016 ($28.90 Mil).

Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Aeolus Pharmaceuticals's Enterprise Value for Today is $0.00 Mil.


Aeolus Pharmaceuticals  (OTCPK:AOLS) Market Cap Explanation

Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the company’s debt. The real price you pay is the Enterprise Value.

Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.


Aeolus Pharmaceuticals Market Cap Related Terms


Aeolus Pharmaceuticals Market Cap Historical Data

* Premium members only.

The historical data trend for Aeolus Pharmaceuticals's Market Cap can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aeolus Pharmaceuticals Market Cap Chart

Aeolus Pharmaceuticals Annual Data
Trend Sep07 Sep08 Sep09 Sep10 Sep11 Sep12 Sep13 Sep14 Sep15 Sep16
Market Cap
Get a 7-Day Free Trial Premium Member Only Premium Member Only 23.21 37.67 33.96 32.70 28.90

Aeolus Pharmaceuticals Quarterly Data
Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17
Market Cap Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 28.90 28.90 28.90 14.45 13.81

AOLS vs RDGL, PCYN, YBAO: Market Cap Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Aeolus Pharmaceuticals's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aeolus Pharmaceuticals Market Cap vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Aeolus Pharmaceuticals's Market Cap distribution charts can be found below:

* The bar in red indicates where Aeolus Pharmaceuticals's Market Cap falls into.



Aeolus Pharmaceuticals Market Cap Calculation

Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.

Aeolus Pharmaceuticals's Market Cap for the fiscal year that ended in Sep. 2016 is calculated as

Market Cap (A: Sep. 2016 )=Share Price (A: Sep. 2016 )*Shares Outstanding (EOP) (A: Sep. 2016 )
=$0.19*152.086
=$28.90

Aeolus Pharmaceuticals's Market Cap for the quarter that ended in Jun. 2017 is calculated as

Market Cap (Q: Jun. 2017 )=Share Price (Q: Jun. 2017 )*Shares Outstanding (EOP) (Q: Jun. 2017 )
=$0.09082*152.086
=$13.81

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Market Cap →
What does a Market Cap of $0.00 Mil mean?
Aeolus Pharmaceuticals (AOLS) has a Market Cap of $0.00 Mil as of Jul. 01, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Aeolus Pharmaceuticals and its competitors.
Is Aeolus Pharmaceuticals' Market Cap too high?
Aeolus Pharmaceuticals' current Market Cap is $0.00 Mil.
How does Aeolus Pharmaceuticals' Market Cap compare to RDGL and PCYN?
Aeolus Pharmaceuticals' Market Cap of $0.00 Mil can be compared against companies in the Drug Manufacturers industry. The industry median Market Cap is 213.67. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Drug Manufacturers company?
The median Market Cap among Drug Manufacturers companies is 213.67, based on 1,020 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Aeolus Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Market Cap is 213.67 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aeolus Pharmaceuticals's current Market Cap is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aeolus Pharmaceuticals stock overvalued right now?
Aeolus Pharmaceuticals (AOLS) has a current Market Cap of $0.00 Mil. The current Market Cap is $0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Aeolus Pharmaceuticals (AOLS), the current Market Cap is $0.00 Mil as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Aeolus Pharmaceuticals Business Description

Address 26361 Crown Valley Parkway, Suite 150, Mission Viejo, CA, USA, 92691
Aeolus Pharmaceuticals Inc is a Southern California-based biopharmaceutical company. The company is developing a platform of novel compounds for use in biodefense, fibrosis, oncology, infectious disease and diseases of the central nervous system. Aeolus is developing its lead compound, AEOL-10150, as a treatment for the lung effects of Acute Radiation Syndrome (Lung-ARS). Aeolus also has two pre-clinical development programs: AEOL 11114 and AEOL 20415.